Abstract

BRCA1 methylation may confer homologous recombination deficiency (HRD) in ovarian carcinomas and loss of methylation can be a mechanism of therapeutic resistance. We sought to develop and validate a clinical grade, quantitative assay for BRCA1 promoter methylation and characterize the impact of BRCA1 methylation in ovarian carcinoma.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call